Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance

Antibiotic-induced perturbation of the human gut flora is expected to play an important role in mediating the relationship between antibiotic use and the population prevalence of antibiotic resistance in bacteria, but little is known about how antibiotics affect within-host resistance dynamics. Here we develop a data-driven model of the within-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. We use blaCTX-M (the most widespread ESBL gene family) and 16S rRNA (a proxy for bacterial load) abundance data from 833 rectal swabs from 133 ESBL-positive patients followed up in a prospective cohort study in three European hospitals. We find that cefuroxime and ceftriaxone are associated with increased blaCTX-M abundance during treatment (21% and 10% daily increase, respectively), while treatment with meropenem, piperacillin-tazobactam, and oral ciprofloxacin is associated with decreased blaCTX-M (8% daily decrease for all). The model predicts that typical antibiotic exposures can have substantial long-term effects on blaCTX-M carriage duration.

[1]  Aki Vehtari,et al.  Rank-Normalization, Folding, and Localization: An Improved Rˆ for Assessing Convergence of MCMC (with Discussion) , 2019, Bayesian Analysis.

[2]  A. Gelman,et al.  Rank-normalization, folding, and localization: An improved R-hat for assessing convergence Rank-Normalization, Folding, and Localization: An Improved (cid:2) R for Assessing Convergence of MCMC An assessing for assessing An improved (cid:2) R for assessing convergence of MCMC , 2020 .

[3]  J. Collins,et al.  Definitions and guidelines for research on antibiotic persistence , 2019, Nature Reviews Microbiology.

[4]  François Blanquart,et al.  Evolutionary epidemiology models to predict the dynamics of antibiotic resistance , 2019, Evolutionary applications.

[5]  M. Jit,et al.  Within-host dynamics shape antibiotic resistance in commensal bacteria , 2018, Nature Ecology & Evolution.

[6]  J. Schrenzel,et al.  Estimating the association between antibiotic exposure and colonisation with ESBL-producing Gram negative bacteria: a multicentre, prospective cohort study. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  M. Lipsitch,et al.  Microbiome as a tool and a target in the effort to address antimicrobial resistance , 2018, Proceedings of the National Academy of Sciences.

[8]  F. Ris,et al.  Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  A. Holmes,et al.  Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study , 2018, BMC Medicine.

[10]  M. Lipsitch,et al.  Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora , 2018, Proceedings of the National Academy of Sciences.

[11]  Peer Bork,et al.  Extensive impact of non-antibiotic drugs on human gut bacteria , 2018, Nature.

[12]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[13]  E. Tacconelli,et al.  Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone , 2017, Antimicrobial Agents and Chemotherapy.

[14]  Johanna C. Braat,et al.  Comparative gut microbiota and resistome profiling of intensive care patients receiving selective digestive tract decontamination and healthy subjects , 2017, Microbiome.

[15]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[16]  Aki Vehtari,et al.  Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC , 2015, Statistics and Computing.

[17]  P. V. van Genderen,et al.  Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. , 2017, The Lancet. Infectious diseases.

[18]  D. Kaye.  Clinical Infectious Diseases , 2017 .

[19]  Molly K. Gibson,et al.  Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome , 2016, Nature Microbiology.

[20]  F. Pasquier,et al.  Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. , 2015, Journal of medical microbiology.

[21]  France Mentré,et al.  Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted , 2014, PLoS Comput. Biol..

[22]  H. Smidt,et al.  Effects of selective digestive decontamination (SDD) on the gut resistome. , 2014, The Journal of antimicrobial chemotherapy.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  Gunnar Rätsch,et al.  Ecological Modeling from Time-Series Inference: Insight into Dynamics and Stability of Intestinal Microbiota , 2013, PLoS Comput. Biol..

[25]  T. Buckley,et al.  Antibiotic Administration Routes Significantly Influence the Levels of Antibiotic Resistance in Gut Microbiota , 2013, Antimicrobial Agents and Chemotherapy.

[26]  Y. Carmeli,et al.  Rectal Swabs Are Suitable for Quantifying the Carriage Load of KPC-Producing Carbapenem-Resistant Enterobacteriaceae , 2013, Antimicrobial Agents and Chemotherapy.

[27]  J. Raes,et al.  Microbial interactions: from networks to models , 2012, Nature Reviews Microbiology.

[28]  D. Perrotin,et al.  Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. , 2011, British journal of clinical pharmacology.

[29]  Alex R. Hall,et al.  The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts , 2010, Nature Reviews Genetics.

[30]  Alimuddin Zumla.  Mandell, Douglas, and Bennett's principles and practice of infectious diseases , 2010, The Lancet Infectious Diseases.

[31]  Sumio Watanabe,et al.  Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory , 2010, J. Mach. Learn. Res..

[32]  B. Levin,et al.  Functional relationship between bacterial cell density and the efficacy of antibiotics. , 2009, The Journal of antimicrobial chemotherapy.

[33]  F. Baquero,et al.  Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[34]  Jane W. Marsh,et al.  Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Gutiérrez,et al.  Activity in vitro of twelve antibiotics against clinical isolates of extended‐spectrum beta‐lactamase producing Escherichia coli , 2007, Journal of basic microbiology.

[36]  David L Paterson.  Resistance in gram-negative bacteria: enterobacteriaceae. , 2006, The American journal of medicine.

[37]  G. Webb,et al.  A model of antibiotic-resistant bacterial epidemics in hospitals. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Carmeli,et al.  High Levels of Antimicrobial Coresistance among Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2005, Antimicrobial Agents and Chemotherapy.

[39]  A. Palva,et al.  Development of an extensive set of 16S rDNA‐targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real‐time PCR , 2004, Journal of applied microbiology.

[40]  F. Baquero,et al.  Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in Spain , 2004, Journal of Clinical Microbiology.

[41]  C. Donskey.  The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  R. Bonnet.  Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes , 2004, Antimicrobial Agents and Chemotherapy.

[43]  D. Paterson,et al.  Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges. , 2003, The Journal of hospital infection.

[44]  Robert Leary,et al.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.

[45]  ACTIVITY IN VITRO , 2003 .

[46]  M. Lipsitch,et al.  Antimicrobial Use and Antimicrobial Resistance: A Population Perspective , 2002, Emerging Infectious Diseases.

[47]  Don S. Lemons,et al.  An Introduction to Stochastic Processes in Physics , 2002 .

[48]  W. Bilker,et al.  Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  D. Livermore,et al.  Detection of β-lactamase-mediated resistance , 2001 .

[50]  Nina Singh,et al.  Control of an outbreak of infection due to extended-spectrum beta-lactamase--producing Escherichia coli in a liver transplantation unit. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  R. Cantón,et al.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  D. Paterson.  Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[53]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Anderson.  A dramatic increase , 1995 .

[55]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[56]  M. Nahata,et al.  Ceftriaxone: a third-generation cephalosporin. , 1985, Drug intelligence & clinical pharmacy.

[57]  L. G. Smith,et al.  Ceftriaxone, a third generation cephalosporin. , 1984, The Journal of the Medical Society of New Jersey.

[58]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[59]  H. Neu,et al.  Cefuroxime, a Beta-Lactamase-Resistant Cephalosporin with a Broad Spectrum of Gram-Positive and -Negative Activity , 1978, Antimicrobial Agents and Chemotherapy.

[60]  D. B. Owen,et al.  Confidence intervals for the coefficient of variation for the normal and log normal distributions , 1964 .